Lantheus to Sell New Jersey Radiopharma Plant and CDMO to PharmaLogic

PharmaLogic Holdings has agreed to buy the contract development and manufacturing (CDMO) business of Lantheus Holdings, along with Lantheus's radiopharmaceutical plant in Springfield, New Jersey. PharmaLogic announced the deal on Nov. 9, 2026. Neither company disclosed the price.

What happened

Lantheus said in a filing with the U.S. Securities and Exchange Commission that it signed the definitive agreement on November 8, 2026. The sale still needs regulatory review and must meet the usual closing conditions. Until then, the two companies will keep operating on their own.

• The site: PharmaLogic describes Springfield as a radiopharmaceutical plant with experience in theranostic manufacturing, research and clinical development.
• The staff: The Springfield team will move to Agilera, PharmaLogic's unit that makes therapeutic radiopharmaceuticals for other companies, once the deal closes.
• The supply deal: The companies will sign a long-term supply agreement. Under it, Agilera will make lutetium Lu 177 dotatate for Lantheus.
• The handover: Lantheus will give PharmaLogic certain transition services right after closing, according to the filing.

The announcement gave no headcount for the site and no expected closing date.

Why it matters

Lutetium Lu 177 dotatate is the active drug in Bravnetsa. Targeted Oncology reported in September that Lantheus won final FDA approval for Bravnetsa in adults with somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. The drug is a radioequivalent of Lutathera. The outlet said it was the first radioligand therapy to win full approval through the generic drug pathway, after a tentative approval in March 2026.

Lantheus chief executive Mary Anne Heino said PharmaLogic is the right long-term owner for the business. She said its skills support a reliable supply of the company's newly approved radiotherapeutic. She also called PharmaLogic an important manufacturing partner for Lantheus's PET products.

PharmaLogic calls itself the only independent CDMO of scale that works only on radiopharmaceuticals. It has more than 45 facilities in the United States, Puerto Rico, Canada and Norway. It says Agilera has more than 15 years of experience with radioligand therapies and now ships an alpha therapy to more than 30 countries. Chief executive Etienne Montagut said the purchase adds to the company's U.S. capacity.

What it means for people in the industry

The Springfield team is set to move to PharmaLogic when the deal closes, according to the release. Neither company has said whether staffing will change. Radiopharma manufacturing and quality staff in the New Jersey area may want to watch for news on the closing date and any hiring at Agilera as it adds U.S. capacity.

See open pharma jobs in the US and Canada

Sources

• PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility, PharmaLogic news release via BioSpace
• Lantheus Holdings, Inc. Form 8-K (Item 8.01, Other Events), U.S. Securities and Exchange Commission
• 177Lu-Dotatate Radioequivalent Earns Final FDA Approval in GEP-NETs, Targeted Oncology